Targeting the Gut-Heart Axis Improves Cardiac Remodeling in a Clinical Scale Model of Cardiometabolic Syndrome

Figures

• 

  Figure 1. Intestinal Barrier Dysfunction, Mucosal Inflammation, Bacterial Translocation, and Systemic and Cardiac mVE Inflammation in MetS Study of the gut-heart axis in control and MetS pigs fed, respectively, normal chow or HFD along with DOCA to induce hypertension over 12 weeks. (A) Intestinal mucus layer thickness (red arrows) by Alcian blue staining of TI sections. (B to D) TI immunofluorescence labeling of (B) ZO-1 and (C) CD16 in crypts and villi (control: n = 7; MetS: n = 7) and (D) relative mRNA expression of inflammatory and NLRP3 signaling genes (control: n = 6; MetS: n = 6). (E) FISH labeling of translocating bacteria within TI crypts (designated by arrowheads) with scrambled probe as negative control (control: n = 7; MetS: n = 7). (F to H) Temporal serum levels of (F) ZO-1, (G) LPS, and (H) TNF-α (control: n = 5; MetS: n = 5). (I, J) LA and LV immunofluorescence labeling of (I) TLR4 and (J) TNFR1 in the LA and LV within CD31+ mVE area (designated by arrowheads) (control: n = 10; MetS: n = 9). All cropped or representative images were acquired at 600× magnification except for Alcian blue staining, which was imaged at 200×. Data are presented as median (Q1-Q3) and were compared…

• 

  Figure 2. LA Inflammation, NLRP3 Activation, CM Apoptosis, and Cytokine Receptor Signaling in MetS (A) Relative mRNA expression of immune cell marker genes in the LA (control: n = 8 vs MetS: n = 8). (B to D) Immunofluorescence labeling of (B) CD16 and (C) CD163 as a percentage of total LA cells in control vs MetS and (D) Ki67 and IGFR labeling of CD16+ Mφs (control: n =10; MetS: n = 9). (E) LA NLRP3 immunofluorescence labeling among CD16+ Mφs, (F) SA+ CMs (designated by arrowheads) (control: n = 10; MetS: n = 9), and (G) relative mRNA expression of NLRP3-associated genes (control: n = 8; MetS: n = 8). (H) TUNEL positivity in total LA cells in both groups (control: n = 10; MetS: n = 9) and (I) within CD16+ and SA+ cell populations (designated by arrowheads) in the MetS group (n = 7), and (J) relative expression of proapoptotic gene mRNA (control: n = 8; MetS: n = 8). (K to N) LA TNFR1 immunofluorescence positivity among (K) SA+ CMs and (L) CD163+ Mφs designated by arrowheads as well as (M) TNFR2 positivity among SA+ CMs (control: n = 10; MetS: n = 9) and (N) relative mRNA expression of TNFR1-associated genes (control: n = 8; MetS: n = 8). LA TLR4 immunofluorescence positivity among (O) SA+…

• 

  Figure 3. Synbiotic Targeting of the Gut-Heart Axis Reduced Cardiac Structural Changes, Intestinal Barrier Dysfunction, Mucosal Mφ Abundance, and Systemic Inflammation in MetS (A) LM growth curve in the presence or absence of fiber in media. (B) Gut-heart axis targeting of MetS using a synbiotic combination of LM and fiber (SLM) or individual LM or fiber. (C, D) Echocardiographic measurements of the (C) LAA and (D) LV wall thickness. (E) SBP and DBP at study termination. (F) TI mucus layer thickness measurements (red arrows) from Alcian blue staining images. Representative images were cropped from 200× magnification. (G) TI crypt immunofluorescence positivity of CD16. (H) Serum levels of TNF-α at the study end. (I) LM abundance measured by quantitative reverse-transcription polymerase chain reaction in cecal samples at study termination. MetS group (red): n = 6; SLM group (blue): n = 6; LM group (pale gray): n = 6; Fib group (speckled): n = 6. Data are presented as median (Q1-Q3) and were compared using the Kruskal-Wallis test. ∗P < 0.05 and ∗∗∗P < 0.001. DBP = diastolic blood pressure; Fib = fiber; LAA = left atrial area; LM = Lactobacillus mucosae; OD = optical density; SBP = systolic…

• 

  Figure 4. Synbiotic Targeting of the Gut-Heart Axis Reduced Bacterial Translocation, Improved Tight Junction Protein Expression, and Reduced Systemic and Cardiac mVE Inflammation in MetS (A) TI FISH labeling of translocating bacteria within crypts and (B) ZO-1 labeling in crypts and villi (MetS: n = 6; SLM: n = 6). (C to F) Time course serum levels of (C) LPS, (D) ZO-1, and (E) TNF-α (at 0, 2, 6, and 12 weeks) and (F) week 12 levels of hs-CRP, IFN-γ, IL-10, PAI-1, and IL-1β (MetS: n = 6; SLM: n = 6). (G, H) LA and LV immunofluorescence labeling of (G) TLR4 and (H) TNFR1 in LA and LV within CD31+ mVE (designated by arrowheads) (MetS: n = 8; SLM: n = 9). Representative images were cropped from 600× magnification. Data are presented as median (Q1-Q3) and were compared using the Mann-Whitney test. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001. hs-CRP = high-sensitivity C-reactive protein; IFN-γ = interferon gamma; IL = interleukin; LPS = lipopolysaccharide; other abbreviations as in Figure 1, Figure 2, Figure 3.

• 

  Figure 5. Synbiotic Targeting of the Gut-Heart Axis Reduced LA Inflammatory Cell Activity, NLRP3 Signaling, and CM Apoptosis and Decreased TNFR1 and TLR4 Activation in MetS (A to E) Immunofluorescence labeling of (A) CD16, (B) CD163, (C) CD11B, and (D) CD3 as a percentage of total LA cells and (E) Ki67 labeling of CD16+ Mφs (MetS: n = 8; SLM: n = 9). (F to H) LA NLRP3 immunofluorescence labeling among (F) CD16+ Mφs and (G) SA+ CMs (designated by arrowheads) (MetS: n = 8; SLM: n = 9) and (H) relative mRNA expression of NLRP3-associated genes (MetS: n = 8; SLM: n = 8). (I) LA TUNEL positivity in total LA cells (MetS: n = 8; SLM: n = 9), (J) relative mRNA expression of proapoptotic gene BAX (MetS: n = 8; SLM: n = 8), and (K) TUNEL positivity within SA+ (designated by arrowheads) (MetS: n = 6; SLM: n = 6) and CD16+ cell populations (designated by arrow heads) (MetS: n = 6; SLM: n = 6). (L-O) LA TNFR1 immunofluorescence positivity among (L) SA+ CMs and (M) CD163+ Mφs (designated by arrowheads), (N) TNFR2 positivity among SA+ CMs (MetS: n = 8; SLM: n = 9), and (O) relative mRNA expression of TNFR1-associated genes (MetS: n = 8; SLM: n = 8). (P-R) LA TLR4 immunofluorescence positivity among (P)…